GW Pharma’s Cannabidiol For Seizures One Step Closer To European Approval
The CHMP has issued a positive opinion for Epidyolex for two rare conditions. The cannabidiol product was approved in the US in 2018.
You may also be interested in...
Pain relief is by far the most popular reason for taking CBD in the UK, a recent survey has revealed. The research by YouGov also finds that a quarter of those who have not tried CBD are tempted to do so.
As a recent meeting of the United Nation's Commission on Narcotic Drugs, the World Health Organization recommended that CBD products with no more than 0.2% THC should not be considered controlled substances. In response, Slovakia down-scheduled CBD. The move and the discussion sparked by WHO's recommendation within the UN 's drug commission shines a new light on debates raging in the UK, where industry is currently facing claims that CBD products with any levels of THC whatsoever should be considered a controlled substance.
Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.